Kevin Winthrop
0000-0002-3892-6947
23 papers found
Refreshing results…
Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
SARS CoV-2 infection among patients using immunomodulatory therapies
To immunosuppress: whom, when and how? That is the question with COVID-19
Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Biologics, spondylitis and COVID-19
Missing publications? Search for publications with a matching author name.